Synopsis
Synopsis
0
USDMF
0
JDMF
0
EU WC
0
KDMF
0
FDA Orange Book
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Cga 184699
2. Cga-184699
3. Fluphenacur
4. Fluphenacur, Monosodium Salt
5. N-(2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenylaminocarbonyl)-2,6-difluorobenzamide
1. 103055-07-8
2. Fluphenacur
3. Lufenuron, (+)-
4. Lufenuron, (-)-
5. 1-(2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl)-3-(2,6-difluorobenzoyl)urea
6. 130841-26-8
7. Cga-184699
8. Nsc-759097
9. N-((2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl)carbamoyl)-2,6-difluorobenzamide
10. N-[[2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]carbamoyl]-2,6-difluorobenzamide
11. 9cr45yms74
12. 130841-22-4
13. Chebi:39384
14. N-{[2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]carbamoyl}-2,6-difluorobenzamide
15. Benzamide, N-(((2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl)amino)carbonyl)-2,6-difluoro-, (+)-
16. Benzamide, N-(((2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl)amino)carbonyl)-2,6-difluoro-, (-)-
17. Ncgc00095978-02
18. 1r754m4918
19. 4629851k7q
20. Dsstox_cid_14357
21. Dsstox_rid_79146
22. Dsstox_gsid_34357
23. Benzamide, N-[[[2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]amino]carbonyl]-2,6-difluoro-
24. N-({[2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]amino}carbonyl)-2,6-difluorobenzamide
25. Lufenurone
26. Lufenuronum
27. Cigna
28. Match (pesticide)
29. 3-[2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]-1-[(2,6-difluorophenyl)carbonyl]urea
30. Lufenuron;(rs)-1-[2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy) Phenyl]-3-(2,6-difluorobenzoyl) Urea
31. N-(2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)-phenyl-aminocarbonyl)-2,6-difluorobenzamide
32. N-[2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)-phenyl-aminocarbonyl]-2,6-difluorobenzamide
33. Program Flavor Tabs
34. Program
35. Cas-103055-07-8
36. Lufenuron [inn:ban]
37. Lufenurone [inn-french]
38. Lufenuronum [inn-latin]
39. Unii-1r754m4918
40. N-(((2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl)amino)carbonyl)-2,6-difluorobenzamide
41. Cga 184699
42. Lufenuron (usp/inn)
43. Lufenuron [inn]
44. Lufenuron [mi]
45. Lufenuron [mart.]
46. Ec 410-690-9
47. Lufenuron [usp-rs]
48. Program [veterinary] (tn)
49. Unii-9cr45yms74
50. Schembl27105
51. Bspbio_002424
52. Mls004712069
53. Spectrum1505355
54. Lufenuron [green Book]
55. Chembl1364906
56. Dtxsid5034357
57. Lufenuron [usp Monograph]
58. Hms3264n09
59. Pharmakon1600-01505355
60. Unii-4629851k7q
61. Sentinel Component Lufenuron
62. Bcp15961
63. Tox21_111542
64. Tox21_300907
65. Mfcd00867616
66. Nsc759097
67. Lufenuron 100 Microg/ml In Methanol
68. Akos022185021
69. Lufenuron Component Of Sentinel
70. Tox21_111542_1
71. Ccg-213976
72. Db11424
73. Nsc 759097
74. N-[[2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]carbamoyl]-2,6-difluoro-benzamide
75. Lufenuron 100 Microg/ml In Acetonitrile
76. Ncgc00095978-01
77. Ncgc00095978-03
78. Ncgc00095978-04
79. Ncgc00095978-06
80. Ncgc00254811-01
81. As-13363
82. Smr001563631
83. Lufenuron 1000 Microg/ml In Acetonitrile
84. Sbi-0207025.p001
85. Db-040412
86. Hy-115584
87. Cs-0088780
88. Ft-0631021
89. L0358
90. Lufenuron, Pestanal(r), Analytical Standard
91. C18434
92. D08150
93. E78989
94. Ab01563233_01
95. Lufenuron (anhydrous) For Veterinary Use
96. 055l078
97. A800670
98. Q412933
99. Sr-01000872762
100. J-521659
101. Sr-01000872762-1
102. Brd-a71774530-001-01-8
103. Brd-a71774530-001-02-6
104. Lufenuron, European Pharmacopoeia (ep) Reference Standard
105. Lufenuron (anhydrous) For Veterinary Use [ep Impurity]
106. Lufenuron, United States Pharmacopeia (usp) Reference Standard
107. Lufenuron For Peak Identification, European Pharmacopoeia (ep) Reference Standard
108. N-(2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenylcarbamoyl)-2,6-difluorobenzamide
109. N-[[2,5-dichloro-4-(1,1,3,4,4,4-hexafluorobutyl)phenyl]carbamoyl]-2,6-difluoro-benzamide
110. (+)-n-(((2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl)amino)carbonyl)-2,6-difluorobenzamide
111. (-)-n-(((2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl)amino)carbonyl)-2,6-difluorobenzamide
112. (rs)-1-(2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl)-3-(2,6-difluorobenzoyl)urea
113. 1-(2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl)-3-(2,6-difluorobenzoyl)-urea
114. Benzamide,n-[[[2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]amino]carbonyl]-2,6-difluoro-
Molecular Weight | 511.1 g/mol |
---|---|
Molecular Formula | C17H8Cl2F8N2O3 |
XLogP3 | 6.4 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 11 |
Rotatable Bond Count | 5 |
Exact Mass | 509.9784228 g/mol |
Monoisotopic Mass | 509.9784228 g/mol |
Topological Polar Surface Area | 67.4 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 677 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Insecticides
Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
86
PharmaCompass offers a list of Lufenuron API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Lufenuron manufacturer or Lufenuron supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Lufenuron manufacturer or Lufenuron supplier.
PharmaCompass also assists you with knowing the Lufenuron API Price utilized in the formulation of products. Lufenuron API Price is not always fixed or binding as the Lufenuron Price is obtained through a variety of data sources. The Lufenuron Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Tox21_300907 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tox21_300907, including repackagers and relabelers. The FDA regulates Tox21_300907 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tox21_300907 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Tox21_300907 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Tox21_300907 supplier is an individual or a company that provides Tox21_300907 active pharmaceutical ingredient (API) or Tox21_300907 finished formulations upon request. The Tox21_300907 suppliers may include Tox21_300907 API manufacturers, exporters, distributors and traders.
click here to find a list of Tox21_300907 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Tox21_300907 CEP of the European Pharmacopoeia monograph is often referred to as a Tox21_300907 Certificate of Suitability (COS). The purpose of a Tox21_300907 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Tox21_300907 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Tox21_300907 to their clients by showing that a Tox21_300907 CEP has been issued for it. The manufacturer submits a Tox21_300907 CEP (COS) as part of the market authorization procedure, and it takes on the role of a Tox21_300907 CEP holder for the record. Additionally, the data presented in the Tox21_300907 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Tox21_300907 DMF.
A Tox21_300907 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Tox21_300907 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Tox21_300907 suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tox21_300907 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Tox21_300907 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Tox21_300907 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Tox21_300907 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tox21_300907 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Tox21_300907 suppliers with NDC on PharmaCompass.
Tox21_300907 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tox21_300907 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tox21_300907 GMP manufacturer or Tox21_300907 GMP API supplier for your needs.
A Tox21_300907 CoA (Certificate of Analysis) is a formal document that attests to Tox21_300907's compliance with Tox21_300907 specifications and serves as a tool for batch-level quality control.
Tox21_300907 CoA mostly includes findings from lab analyses of a specific batch. For each Tox21_300907 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tox21_300907 may be tested according to a variety of international standards, such as European Pharmacopoeia (Tox21_300907 EP), Tox21_300907 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tox21_300907 USP).